Alzheimer's disease. Alzheimer's disease with late onset
Conditions
Interventions
Intervention 1: First intervention group: In addition to taking routine medications (10 mg Donepezil/6 mg Rivastigmine) once daily, patients receive 140 mg Silymarin tablets (Livergol 140 mg
Goldaru Pharmaceutical Company
Isfahan, Iran) orally three times daily with an interval of eight hours for 6 months. Intervention 2: Control group: In addition to taking routine medications (10 mg Donepezil/6 mg Rivastigmine) once
Isfahan, Iran) orally three times daily with an interval of eight hours for 6 months. Intervention 3: Second intervention group: In addition to taking routine medications (10 mg Donepezil/6 mg Rivasti
Abidi Pharmaceutical Company
Tehran, Iran) orally three times daily with an interval of eight hours for 6 months.
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
60 Years to 80 Years
Inclusion criteria
Inclusion criteria: The patient has sporadic Alzheimer's disease. The patient has a mild degree of Alzheimer's disease. The patient has dyslipidemia. Patients whose Alzheimer's disease has been confirmed by clinical evaluation or imaging techniques and biochemical tests by a neurologist.
Exclusion criteria
Exclusion criteria: The patient has no history of viral hepatitis. The patient has not had alcohol misuse, smoking or drug abuse in the last month. The patient should not take chemotherapy drugs. The patient does not have active rheumatic disorders. The patient does not have diabetes and uncontrolled hypertension. The patient has no history of brain surgery. The patient does not have advanced heart failure, acute cardiovascular disease, or chronic renal failure. The patient does not have hypothyroidism.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| N-acetyl-aspartate (NAA) metabolite. Timepoint: Before and after the intervention (6 months). Method of measurement: Part per million (ppm) in MR spectroscopy and percentage.;Amyloid beta-42 (Aß42). Timepoint: Before and after the intervention (6 months). Method of measurement: ELISA kit. | — |
Secondary
| Measure | Time frame |
|---|---|
| Low Density Lipoprotein Receptor-Related Protein-1 (LRP1). Timepoint: Before and after the intervention (6 months). Method of measurement: ELISA kit.;Lactate (Lac) metabolite. Timepoint: Before and after the intervention (6 months). Method of measurement: Part per million (ppm) in MR spectroscopy and percentage.;Choline (Cho) metabolite. Timepoint: Before and after the intervention (6 months). Method of measurement: Part per million (ppm) in MR spectroscopy and percentage.;Myoinositol (mI) metabolite. Timepoint: Before and after the intervention (6 months). Method of measurement: Part per million (ppm) in MR spectroscopy and percentage.;Creatine (Cr) metabolite. Timepoint: Before and after the intervention (6 months). Method of measurement: Part per million (ppm) in MR spectroscopy and percentage.;Correlation between imaging and blood biomarkers with clinical findings. Timepoint: Before and after the intervention (6 months). Method of measurement: Percent with Pearson statistical test.;Mini-Mental State Exam (MMSE). Timepoint: Before and after the intervention (6 months). Method of measurement: MMSE questionnaire.;Clinical dementia rating (CDR). Timepoint: Before and after the intervention (6 months). Method of measurement: CDR questionnaire.;High density lipoprotein (HDL). Timepoint: Before and after the intervention (6 months). Method of measurement: Spectrophotometry.;Low density lipoprotein (LDL). Timepoint: Before and after the intervention (6 months). Method of measurement: Spectrophotometry.;Triglycerides (TG). Timepoint: Before and after the intervention (6 months). Method of measurement: Spectrophotometry.;Catalase (CAT). Timepoint: Before and after the intervention (6 months). Method of measurement: Spectrophotometry.;Superoxide dismutase (SOD). Timepoint: Before and after the intervention (6 months). Method of measurement: Spectrophotometry.;Malondialdehyde (MDA). Timepoint: Before and after the intervention (6 months). Method of measurement: Spectrophoto | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAuob Rustamzadeh
Iran University of Medical Sciences
Outcome results
None listed